|
시장보고서
상품코드
2077970
만성 간질환 치료제 시장 : 치료법별(항바이러스제), 질환별, 유통 형태별, 지역별Chronic Liver Diseases Therapeutics Market, By Treatment Type Antiviral Drugs, By Disease Type, By Distribution type, And By Region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa) |
||||||
만성 간질환 치료제 시장은 2026년에 207억 8,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 434억 1,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 11.1%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 207억 8,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 11.10% | 2033년 시장 규모 예측: | 434억 1,000만 달러 |
간은 체내에서 가장 큰 고형 내장 기관으로, 음식물의 소화에 필요한 담즙을 생성하고, 음식물을 에너지로 전환하며, 모든 세포 활동과 생체 활동에 필요한 영양소를 저장하는 등 체내의 화학제품을 적절한 수준으로 유지하는 등 다양한 역할을 수행하고 있습니다. 따라서 간 기능이 정상적으로 작동하지 않으면 A형, B형, C형 간염, 원발성 간경변, 종양 등 많은 중증 질환을 유발할 가능성이 있습니다. 간 기능 이상을 유발하는 주요 원인으로는 비만, 과도한 음주, 유전성 질환 등이 있습니다. 간 질환의 치료법으로는 항바이러스제, 면역억제제, 백신, 면역글로불린, 코르티코스테로이드, 표적 치료, 화학요법 등이 사용될 수 있습니다. 또한, 만성 간 질환에는 간염, 자가면역 질환, 비알코올성 지방간 질환(NAFLD), 암, 유전성 질환 등이 포함됩니다.
시장 역학
만성 간질환 환자 수의 증가, 간질환 치료를 위한 신기술 개발을 목표로 한 연구 개발 활동의 활성화, 그리고 시장에서 사업을 전개하는 주요 기업들의 합병, 인수, 제휴, 공동 연구와 같은 비유기적 성장 전략의 확대가 예측 기간 동안 전 세계 만성 간질환 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 예를 들어, 2022년 12월, 비만 및 간 질환 치료를 목적으로 하는 신규 펩타이드 계열 치료제 개발에 주력하는 임상 단계의 바이오의약품 기업인 Altimmune, Inc.는 비알코올성 지방간 질환을 대상으로 한 Pemvidutide의 24주(12주 연장) 임상시험에서 간 내 지방 함량 및 간 염증을 획기적으로 감소시킬 가능성을 보여주는 긍정적인 톱라인 결과를 발표했습니다. 또한, 2022년 1월에는 지방간 질환에 대한 신약 개발에 주력하고 있는 임상 단계의 바이오의약품 기업인 Madrigal Pharmaceuticals, Inc.가 자사의 개발이 가장 진전된 임상 후보물질인 레스메틸롬에 대해 위약 대조· 이중 맹검 방식으로 진행된 제3상 MAESTRO-NAFLD(비알코올성 지방간 질환) 안전성 시험의 톱라인 임상 데이터를 발표하여, 양호한 결과가 나타났습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안을 정리한 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 만성 간질환 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 세계 만성 간질환 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 만성 간질환 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 만성 간질환 치료제 시장 : 치료 유형별, 2021-2033년
제5장 세계의 만성 간질환 치료제 시장 : 질환 유형별, 2021-2033년
제6장 세계의 만성 간질환 치료제 시장 : 유통 형태별, 2021-2033년
제7장 세계의 만성 간질환 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.09Chronic Liver Diseases Therapeutics Market is estimated to be valued at USD 20.78 Bn in 2026 and is expected to reach USD 43.41 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 20.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.10% | 2033 Value Projection: | USD 43.41 Bn |
The liver is the largest solid internal organ of the body and performs various roles that include the creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases, which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper liver functioning are obesity, excessive alcohol consumption, and genetic disorder. The treatment options available to treat liver diseases include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.
Market Dynamics
The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period. For instance, in December 2022, Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver disease, announced positive topline results from its 24-week (12-week extension) trial of Pemvidutide for non-alcoholic fatty liver disease, showing the potential to dramatically lower liver fat content and liver inflammation. Moreover, in January 2022, Madrigal Pharmaceuticals, Inc. l is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, announced positive topline clinical data from the placebo-controlled, double-blind version of its phase 3 MAESTRO-NAFLD (Non-Alcoholic Fatty Liver Disease) safety study of Resmetirom.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
- Global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Chronic Liver Diseases Therapeutics market.
Detailed Segmentation:
- Global Chronic Liver Diseases Therapeutics Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
- Antiviral drugs
- Immunosuppressants
- Vaccines
- Immunoglobulins
- Corticosteroids
- Targeted Therapy
- Chemotherapy
- Global Chronic Liver Diseases Therapeutics Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
- Hepatitis
- Autoimmune Diseases
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Cancer
- Genetic Disorders
- Others
- Global Chronic Liver Diseases Therapeutics Market, By Distribution type (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Chronic Liver Diseases Therapeutics, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Astellas Pharma Inc
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Sanofi S.A
- Pfizer Inc.
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Watson Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Alnylam Pharmaceuticals, Inc.
- Protagonist Therapeutics, Inc.
- Dicerna Pharmaceuticals, Inc.
- Endo International
- Provectus Biopharmaceuticals Inc.
- MAX BioPharma, Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution type
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Chronic Liver Diseases Therapeutics Market, By Treatment Type, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Antiviral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Segment Trends
5. Global Chronic Liver Diseases Therapeutics Market, By Disease Type, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Genetic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
6. Global Chronic Liver Diseases Therapeutics Market, By Distribution type, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021€"2033, (US$ Bn)
7. Global Chronic Liver Diseases Therapeutics Market, By Regions, 2021€"2033 (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Disease Type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Distribution type, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021€"2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Astellas Pharma Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Gilead Sciences
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi S.A
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Valeant Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Watson Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Theratechnologies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Alnylam Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Protagonist Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Dicerna Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Endo International
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Provectus Biopharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- MAX BioPharma, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Astellas Pharma Inc
9. Section
- References
- Research Methodology
- About us and Sales Contact
